Andrew Hotson

1.8k total citations
22 papers, 1.1k citations indexed

About

Andrew Hotson is a scholar working on Physiology, Oncology and Immunology. According to data from OpenAlex, Andrew Hotson has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 8 papers in Oncology and 6 papers in Immunology. Recurrent topics in Andrew Hotson's work include Adenosine and Purinergic Signaling (10 papers), Click Chemistry and Applications (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Andrew Hotson is often cited by papers focused on Adenosine and Purinergic Signaling (10 papers), Click Chemistry and Applications (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Andrew Hotson collaborates with scholars based in United States, Australia and China. Andrew Hotson's co-authors include Mary Beth Mudgett, Hongjun Shu, Kim Orth, Renée J. Chosed, Richard A. Miller, Stephen B. Willingham, Yajuan Cao, Garry P. Nolan, Eric A. Schmelz and Mark T. Keegan and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Andrew Hotson

21 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Hotson United States	12	432	402	283	233	172	22	1.1k
Stuart W. Hicks United States	18	77 0.2×	553 1.4×	247 0.9×	146 0.6×	58 0.3×	28	1.1k
Norihiro Nakamura Japan	13	123 0.3×	504 1.3×	378 1.3×	105 0.5×	73 0.4×	17	973
Robert A. Spooner United Kingdom	22	108 0.3×	794 2.0×	664 2.3×	137 0.6×	80 0.5×	40	1.5k
Christopher Tipper United States	9	53 0.1×	840 2.1×	158 0.6×	73 0.3×	84 0.5×	14	1.3k
Elena Mossessova United States	8	97 0.2×	1.0k 2.6×	58 0.2×	141 0.6×	90 0.5×	8	1.3k
Christopher J. Shoemaker United States	14	103 0.2×	1.4k 3.5×	76 0.3×	119 0.5×	77 0.4×	23	1.8k
Jennifer Oki United States	5	123 0.3×	1.2k 3.0×	135 0.5×	80 0.3×	31 0.2×	5	1.5k
Patricia Berninsone United States	19	170 0.4×	720 1.8×	154 0.5×	31 0.1×	28 0.2×	30	1.1k
Gabriel Schlenstedt Germany	28	182 0.4×	2.3k 5.7×	181 0.6×	96 0.4×	26 0.2×	45	2.5k
Marije Marsman Netherlands	8	25 0.1×	687 1.7×	295 1.0×	60 0.3×	200 1.2×	10	1.5k

Countries citing papers authored by Andrew Hotson

Since Specialization

Citations

This map shows the geographic impact of Andrew Hotson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Hotson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Hotson more than expected).

Fields of papers citing papers by Andrew Hotson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Hotson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Hotson. The network helps show where Andrew Hotson may publish in the future.

Co-authorship network of co-authors of Andrew Hotson

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Hotson. A scholar is included among the top collaborators of Andrew Hotson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Hotson. Andrew Hotson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Motwani, Mona, Julia Bar, Nicolas Girard, et al.. (2021). P60.12 Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC. Journal of Thoracic Oncology. 16(10). S1169–S1170. 5 indexed citations

Willingham, Stephen B., Andrew Hotson, & Richard A. Miller. (2020). Targeting the A2AR in cancer; early lessons from the clinic. Current Opinion in Pharmacology. 53. 126–133. 37 indexed citations

Voss, Martin H., Andrew Hotson, Stephen B. Willingham, et al.. (2020). CD68+ tumor-associated myeloid cells as the target of adenosine-induced gene products and predictor of response to adenosine blockade with ciforadenant (cifo) in renal cell cancer (RCC).. Journal of Clinical Oncology. 38(15_suppl). 5025–5025. 1 indexed citations

Khodadoust, Michael S., Tatyana Feldman, Dok Hyun Yoon, et al.. (2020). Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma. Blood. 136(Supplement 1). 19–20. 7 indexed citations

Luke, Jason J., John D. Powderly, Jaime R. Merchan, et al.. (2019). Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.. Journal of Clinical Oncology. 37(15_suppl). 2505–2505. 36 indexed citations

Willingham, Stephen B., Po Y. Ho, Andrew Hotson, et al.. (2018). A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models. Cancer Immunology Research. 6(10). 1136–1149. 162 indexed citations

Willingham, Stephen B., Andrew Hotson, Ginna G. Laport, et al.. (2018). Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444. Annals of Oncology. 29. viii403–viii404. 7 indexed citations

Willingham, Stephen B., Andrew Hotson, Po Y. Ho, et al.. (2017). Abstract 5593: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies. Cancer Research. 77(13_Supplement). 5593–5593. 1 indexed citations

Ho, Po Y., et al.. (2017). Abstract 5598: Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models. Cancer Research. 77(13_Supplement). 5598–5598. 1 indexed citations

10.

McCaffery, Ian, Ginna G. Laport, Andrew Hotson, et al.. (2016). Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers. Annals of Oncology. 27. vi124–vi124. 6 indexed citations

11.

Willingham, Stephen B., Andrew Hotson, Po Y. Ho, et al.. (2016). Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies. Cancer Immunology Research. 4(11_Supplement). PR04–PR04. 7 indexed citations

12.

Willingham, Stephen B., Po Y. Ho, Robert D. Leone, et al.. (2016). Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1. Cancer Research. 76(14_Supplement). 2337–2337. 4 indexed citations

13.

Hotson, Andrew, Smita Gopinath, Monica Nicolau, et al.. (2016). Coordinate actions of innate immune responses oppose those of the adaptive immune system during Salmonella infection of mice. Science Signaling. 9(410). ra4–ra4. 20 indexed citations

14.

Spitzer, Matthew H., Pier Federico Gherardini, Gabriela K. Fragiadakis, et al.. (2015). An interactive reference framework for modeling a dynamic immune system. Science. 349(6244). 1259425–1259425. 171 indexed citations

15.

Gopinath, Smita, Andrew Hotson, Jennifer L. Johns, Garry P. Nolan, & Denise M. Monack. (2013). The Systemic Immune State of Super-shedder Mice Is Characterized by a Unique Neutrophil-dependent Blunting of TH1 Responses. PLoS Pathogens. 9(6). e1003408–e1003408. 25 indexed citations

16.

Spitzer, Matthew H., Andrew Hotson, Sean C. Bendall, Edgar G. Engleman, & Garry P. Nolan. (2013). Systematically defining murine immunity at the phenotypic and functional levels via mass cytometry (P3283). The Journal of Immunology. 190(Supplement_1). 192.27–192.27. 1 indexed citations

17.

Kim, Jung‐Gun, Kyle W. Taylor, Andrew Hotson, et al.. (2008). XopD SUMO Protease Affects Host Transcription, Promotes Pathogen Growth, and Delays Symptom Development inXanthomonas-Infected Tomato Leaves . The Plant Cell. 20(7). 1915–1929. 133 indexed citations

18.

Hotson, Andrew, et al.. (2004). Characterization of the Xanthomonas AvrXv4 Effector, a SUMO Protease Translocated into Plant Cells. Molecular Plant-Microbe Interactions. 17(6). 633–643. 145 indexed citations

19.

Hotson, Andrew & Mary Beth Mudgett. (2004). Cysteine proteases in phytopathogenic bacteria: identification of plant targets and activation of innate immunity. Current Opinion in Plant Biology. 7(4). 384–390. 88 indexed citations

20.

Hotson, Andrew, Renée J. Chosed, Hongjun Shu, Kim Orth, & Mary Beth Mudgett. (2003). Xanthomonas type III effector XopD targets SUMO‐conjugated proteins in planta. Molecular Microbiology. 50(2). 377–389. 214 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact